These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 9281234)

  • 1. [Insulin therapy in type II diabetes].
    Beyer J; Küstner E
    Wien Med Wochenschr; 1997; 147(9):211-6. PubMed ID: 9281234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Insulin therapy in patients with type 2 diabetes].
    Siegmund T; Schumm-Draeger PM
    MMW Fortschr Med; 2008 May; 150(18):32-5; quiz 36. PubMed ID: 18533606
    [No Abstract]   [Full Text] [Related]  

  • 3. [Insulin therapy in type 2 diabetes].
    Hummel M
    MMW Fortschr Med; 2011 Jun; 153(23):56-9, 61; quiz 62. PubMed ID: 21688497
    [No Abstract]   [Full Text] [Related]  

  • 4. [Insulin therapy of type 2 diabetes: from simple to flexible--three strategies are available].
    Liebl A
    MMW Fortschr Med; 2012 Nov; 154 Spec No 3():66-71; quiz 72-3. PubMed ID: 23724722
    [No Abstract]   [Full Text] [Related]  

  • 5. [Intensified conventional insulin therapy in patients with type 2 diabetes mellitus. Positive long-term effects of insulin lispro on metabolic control and microalbuminuria].
    Jungmann E; Helling T; Jungmann G; Mertens C; Snelting U
    Fortschr Med Orig; 2001 Jan; 118(4):141-6. PubMed ID: 11217677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Control of diabetes mellitus].
    Daweke H
    Verh Dtsch Ges Inn Med; 1990; 96():175-82. PubMed ID: 2092437
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
    Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [National practice guideline for diabetes. Managing your diabetic patient properly].
    Stiefelhagen P
    MMW Fortschr Med; 2002 Jul; 144(27-28):4-8, 10. PubMed ID: 12198877
    [No Abstract]   [Full Text] [Related]  

  • 9. [A simple regimen only lasts a short time].
    Einecke D
    MMW Fortschr Med; 2007 Oct; 149(40):12-4. PubMed ID: 18018501
    [No Abstract]   [Full Text] [Related]  

  • 10. [Diabetes mellitus type II: when convert to insulin?].
    Bianda TL; Spinas GA
    Praxis (Bern 1994); 1997 Sep; 86(38):1453-7. PubMed ID: 9381045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Summaries for patients. Inhaled insulin with or instead of oral medications for type 2 diabetes.
    Ann Intern Med; 2005 Oct; 143(8):I28. PubMed ID: 16230717
    [No Abstract]   [Full Text] [Related]  

  • 13. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
    Blicklé JF; Hancu N; Piletic M; Profozic V; Shestakova M; Dain MP; Jacqueminet S; Grimaldi A
    Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intensified therapy with insulin analogs in type 2 diabetes: normalizing metabolism and maintaining body weight?].
    Jungmann E; Helling T; Jungmann G; Mertens C; Snelting U
    MMW Fortschr Med; 2000 Oct; 142(43):48. PubMed ID: 11098614
    [No Abstract]   [Full Text] [Related]  

  • 15. [Improvement in glycemic control, cardiovascular risk factors and anthropometric data in type 2 diabetic patients after the switch from biphasic human insulin to biphasic premix analog insulin aspart].
    Gero L; Gyimesi A; Hidvégi T; Jánosi I
    Orv Hetil; 2009 Aug; 150(35):1637-47. PubMed ID: 19692308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal insulin intensification in type 2 diabetes: a key role for GLP-1 receptor agonists.
    Charbonnel PB
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S1-6S2. PubMed ID: 26774014
    [No Abstract]   [Full Text] [Related]  

  • 17. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
    Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
    Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [HbA1c is too high despite tablets. With single injections toward better blood glucose values].
    MMW Fortschr Med; 2004 Mar; 146(10):43. PubMed ID: 15347083
    [No Abstract]   [Full Text] [Related]  

  • 19. [Early insulin treatment in type 2 diabetes--yes].
    Schumm-Draeger PM
    Dtsch Med Wochenschr; 2013 May; 138(18):956. PubMed ID: 23613375
    [No Abstract]   [Full Text] [Related]  

  • 20. [The new oral antidiabetics. Type 2 diabetes under control only with tablets?].
    Hanefeld M
    MMW Fortschr Med; 2001 May; 143(21):38-42. PubMed ID: 11420830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.